Hjem › Spiserørkreft › Tennessee
Kliniske studier for Spiserørkreft i Tennessee
21 studier for Spiserørkreft søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07283939A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07090499Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07519655DESTINY-PANTUMOUR04
- Research Site, Nashville
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06047379Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07431281A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- The University Of Tennessee Health Science Center, Memphis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT03526835A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jul. 2026 · NCT06695845A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT04389632Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06239194Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mar. 2026 · NCT00899626cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jan. 2026 · NCT07181473SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.